Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer

A. J. Montero, C. M. Diaz-Montero, Y. E. Deutsch, J. Hurley, L. G. Koniaris, T. Rumboldt, S. Yasir, M. Jorda, E. Garret-Mayer, E. Avisar, J. Slingerland, O. Silva, C. Welsh, K. Schuhwerk, P. Seo, M. D. Pegram, S. Glück

Research output: Contribution to journalArticlepeer-review

68 Scopus citations

Fingerprint

Dive into the research topics of 'Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences